Adage Capital Partners’s Astria Therapeutics ATXS Stock Holding History

Adage Capital Partners’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-900,000	Closed	-$11.8M	–	968
2025 Q4	$11.8M	Buy	900,000 +66,000	+8%	+$788K	0.02%	633
2025 Q3	$6.07M	Sell	834,000 -41,000	-5%	-$277K	0.01%	713
2025 Q2	$4.69M	Buy	875,000 +286,800	+49%	+$1.39M	0.01%	710
2025 Q1	$3.14M	Sell	588,200 -125,000	-18%	-$875K	0.01%	738
2024 Q4	$6.38M	Sell	713,200 -54,743	-7%	-$581K	0.01%	687
2024 Q3	$8.46M	Sell	767,943 -52,057	-6%	-$579K	0.01%	650
2024 Q2	$7.46M	Sell	820,000 -781,097	-49%	-$7.63M	0.01%	655
2024 Q1	$22.5M	Buy	+1,601,097	New	+$19.9M	0.04%	416

Adage Capital Partners's ATXS Position: Q1 2026 in Review

Adage Capital Partners sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 900,000 shares — an estimated $11.8M sold.

Adage Capital Partners first reported a position in ATXS in Q1 2024 and held it in 8 quarters. The position peaked at $22.5M in Q1 2024. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

Adage Capital Partners reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
Adage Capital Partners sold 900,000 Astria Therapeutics shares in Q1 2026, an estimated $11.8M.
Adage Capital Partners first reported a position in Astria Therapeutics in Q1 2024 and held it in 8 quarters.
Adage Capital Partners's Astria Therapeutics position peaked at $22.5M in Q1 2024.
0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Adage Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.